EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Measurable disease as baseline criterion for response assessment in glioblastoma: A comparison of PET -based (PET RANO 1.0) and MRI-based (RANO) assessments

Katharina J Müller iD, Robert Forbrig iD, Jonas Reis, Lilian Wiegand, Enio Barci, Sophie C Kunte, Lena Kaiser, Stephan Schönecker iD, Christian Schichor iD, Patrick N Harter, Niklas Thon, Louisa von Baumgarten iD und 2 weitere

Neuro-Oncology · 12.01.2025 · 27 (1) · 77-88

DOI: 10.1093/neuonc/noae208 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Neuro-Oncology, online erschienen am 19.11.2024. Verfasst von Katharina J Müller und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, LMU University Hospital, LMU Munich, Munich, Germany. Hauptthemen laut MEDLINE: Glioblastoma, Positron-Emission Tomography, Magnetic Resonance Imaging, Brain Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Thomas Kirch Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recently, criteria based on amino acid positron emission tomography (PET) have been proposed for response assessment in diffuse gliomas (PET RANO 1.0). In this study, we compare the prevalence of measurable disease according to PET RANO 1.0 with magnetic resonance imaging (MRI)-based Response Assessment in Neuro-Oncology (RANO) criteria in glioblastoma.

Methods

We retrospectively identified patients with newly diagnosed IDH-wild-type glioblastoma who underwent [18F] Fluoroethyltyrosine (FET) PET and MRI after resection or biopsy and before radio-/radiochemotherapy. Two independent investigators analyzed measurable disease according to PET RANO 1.0 or MRI-RANO criteria. Additionally, lesion size, congruency patterns, and uptake intensity on [18F]FET PET images were assessed.

Results

We evaluated 125 patients including 49 cases after primary resection and 76 cases after biopsy. Using PET criteria, 113 out of 125 patients (90.4%) had measurable disease, with a median PET-positive volume of 15.34 cm3 (8.83–38.03). With MRI, a significantly lower proportion of patients had measurable disease (57/125, 45.6%; P < .001) with a median sum of maximum cross-sectional diameters of 35.65 mm (26.18–45.98). None of the 12 patients without measurable disease on PET had measurable disease on MRI. Contrariwise, 56/68 patients (82.4%) without measurable disease on MRI exhibited measurable disease on PET. Clinical performance status correlated significantly with PET-positive volume and MRI-based sum of diameters (P < .0059, P < .0087, respectively). Conclusions [18F]FET PET identifies a higher number of patients with measurable disease compared to conventional MRI in newly diagnosed glioblastoma. PET-based assessment may serve as a novel baseline parameter for evaluating residual tumor burden and improving patient stratification in glioblastoma studies. Further validation in prospective trials is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaPositron-Emission TomographyMagnetic Resonance ImagingBrain NeoplasmsHumansFemaleMaleMiddle AgedRetrospective StudiesAgedAdultFollow-Up StudiesPrognosisRadiopharmaceuticalsTyrosineYoung AdultAged, 80 and over

Stichwörter der Autor:innen

MRI RANOPET RANO 1.0glioblastomaresidual tumor burdenresponse assessment

Substanzen

RadiopharmaceuticalsTyrosine(18F)fluoroethyltyrosine

Autor:innen und Institutionen

  • Department of Neurology, LMU University Hospital, LMU Munich, Munich, Germany.
  • Institute of Neuroradiology, LMU University Hospital, LMU Munich, Munich, Germany.
  • Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
  • Bayerisches Zentrum für Krebsforschung (BZKF), Partner Site Munich, Munich, Germany.
  • Department of Radiation Oncology, LMU University Hospital, LMU Munich, Munich, Germany.
  • Department of Neurosurgery, LMU University Hospital, LMU Munich, Munich, Germany.

ORCID-Profile: Katharina J Müller, Robert Forbrig, Stephan Schönecker, Christian Schichor, Louisa von Baumgarten, Matthias Preusser, Nathalie L Albert

Förderung

  • Thomas Kirch Stiftung

Zitieren

APA

Müller, K. J., Forbrig, R., Reis, J., Wiegand, L., Barci, E., Kunte, S. C., Kaiser, L., Schönecker, S., Schichor, C., Harter, P. N., Thon, N., von Baumgarten, L., Preusser, M., & Albert, N. L. (2025). Measurable disease as baseline criterion for response assessment in glioblastoma: A comparison of PET -based (PET RANO 1.0) and MRI-based (RANO) assessments. Neuro-Oncology, 27(1), 77-88. https://doi.org/10.1093/neuonc/noae208

Vancouver

Müller KJ, Forbrig R, Reis J, Wiegand L, Barci E, Kunte SC, et al. Measurable disease as baseline criterion for response assessment in glioblastoma: A comparison of PET -based (PET RANO 1.0) and MRI-based (RANO) assessments. Neuro-Oncology. 2025;27(1):77-88. doi:10.1093/neuonc/noae208

BibTeX
@article{Mller2025,
  author = {Müller, Katharina J and Forbrig, Robert and Reis, Jonas and Wiegand, Lilian and Barci, Enio and Kunte, Sophie C and Kaiser, Lena and Schönecker, Stephan and Schichor, Christian and Harter, Patrick N and Thon, Niklas and von Baumgarten, Louisa and Preusser, Matthias and Albert, Nathalie L},
  title = {Measurable disease as baseline criterion for response assessment in glioblastoma: A comparison of PET -based (PET RANO 1.0) and MRI-based (RANO) assessments},
  journal = {Neuro-Oncology},
  year = {2025},
  volume = {27},
  number = {1},
  pages = {77--88},
  doi = {10.1093/neuonc/noae208}
}
Kostenlos starten →